Vidarbha News

Propulsion of Desmoid Tumors Clinical Trial Pipeline as Novel and Extensive 12+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of Desmoid Tumors Clinical Trial Pipeline as Novel and Extensive 12+ Therapies Likely to Enter in the Domain | DelveInsight

September 03
13:16 2023
Propulsion of Desmoid Tumors Clinical Trial Pipeline as Novel and Extensive 12+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Desmoid Tumors Pipeline constitutes 12+ key companies continuously working towards developing 12+ Desmoid Tumors Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Desmoid Tumors Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Desmoid Tumors NDA approvals (if any), and product development activities comprising the technology, Desmoid Tumors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Desmoid Tumors Pipeline treatment landscape of the report, click here @ Desmoid Tumors Pipeline Outlook

 

Key Takeaways from the Desmoid Tumors Pipeline Report

  • DelveInsight’s Desmoid Tumors Pipeline analysis depicts a robust space with 12+ active players working to develop 12+ pipeline treatment therapies.
  • The leading companies working in the Desmoid Tumors market include Ayala Pharmaceuticals, Inc., SpringWorks Therapeutics, Recursion Pharmaceuticals Inc., Iterion Therapeutics, 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPact, Intas Pharmaceutical, Jina pharmaceuticals, and others.
  • Promising Desmoid Tumors Pipeline Therapies in the various stages of development include Nirogacestat oral tablet, AL102, Cryoablation, Tegavivint, Imatinib, Sirolimus, Nab-Rapamycin, E7386, and others.
  • On June 2023, SpringWorks Therapeutics Inc. announced a study of phase 3 clinical trials for Nirogacestat oral tablet. This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive Nirogacestat.
  • On August 2023, Ayala Pharmaceuticals Inc. announced a study of phase 2 & 3 clinical trials for AL102. The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

 

Desmoid Tumors Overview

Desmoid tumors is an abnormal growth that arises from connective tissue. “Desmoid”” comes from the Greek word desmos, which means tendon or band-like. These are also known as aggressive fibromatosis or desmoid-type fibromatosis.

 

For further information, refer to the detailed Desmoid Tumors Unmet Needs, click here for Desmoid Tumors Ongoing Clinical Trial Analysis

 

Desmoid Tumors Emerging Drugs Profile

  • Nirogacestat: SpringWorks Therapeutics
  • Tegavivint: Iterion Therapeutics

 

Desmoid Tumors Pipeline Therapeutics Assessment

There are approx. 12+ key companies which are developing the therapies for Desmoid Tumors. The companies which have their Desmoid Tumors drug candidates in the most advanced stage, i.e. phase III include, SpringWorks Therapeutics.

 

Request a sample and discover the recent advances in Desmoid Tumors Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Desmoid Tumors Segmentation

 

Desmoid Tumors Drugs and Companies

  • Nirogacestat Oral Tablet: SpringWorks Therapeutics Inc.
  • AL102: Ayala Pharmaceuticals Inc.
  • Nirogacestat: Stanford University.

 

Desmoid Tumors Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

  

Some of the Companies in the Desmoid Tumors Therapeutics Market include-

Ayala Pharmaceuticals, Inc., SpringWorks Therapeutics, Recursion Pharmaceuticals Inc., Iterion Therapeutics, 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPact, Intas Pharmaceutical, Jina pharmaceuticals, and others.

 

Dive deep into rich insights for drugs for the Desmoid Tumors Pipeline, Click here @ Desmoid Tumors Unmet Needs and Analyst Views

 

Scope of the Desmoid Tumors Pipeline Report

  • Coverage- Global
  • Companies- Ayala Pharmaceuticals, Inc., SpringWorks Therapeutics, Recursion Pharmaceuticals Inc., Iterion Therapeutics, 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPact, Intas Pharmaceutical, Jina pharmaceuticals, and others.
  • Therapies- Nirogacestat oral tablet, AL102, Cryoablation, Tegavivint, Imatinib, Sirolimus, Nab-Rapamycin, E7386, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Desmoid Tumors Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Desmoid Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Desmoid Tumors – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Desmoid Tumors Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Nirogacestat: SpringWorks Therapeutics
  11. Mid Stage Products (Phase II)
  12. Tegavivint: Iterion Therapeutics
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. Endoxifen: Intas Pharmaceuticals/Jina Pharmaceuticals
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. Collagenase injection: BioSpecifics Technologies Corp.
  19. Drug profiles in the detailed report…..
  20. Inactive Products
  21. Desmoid Tumors Key Companies
  22. Desmoid Tumors Key Products
  23. Desmoid Tumors- Unmet Needs
  24. Desmoid Tumors- Market Drivers and Barriers
  25. Desmoid Tumors- Future Perspectives and Conclusion
  26. Desmoid Tumors Analyst Views
  27. Desmoid Tumors Key Companies
  28. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories